Registry Following People With Psoriasis or Psoriatic Arthritis Treated With IL-23 Inhibitors
Follows people with psoriatic disease taking guselkumab or risankizumab in routine care.
Plain-language title generated from the registry record
Registry title: Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
Key facts
- Where
- San José, Costa RicaSee the site
Where in Costa Rica
- Caja Costarricense del Seguro SocialSan José, Costa RicaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Caja Costarricense de Seguro Social
- Trial code
- NCT07448402
- Record updated
- 9 March 2026
- Original description
The goal of this observational registry study is to evaluate the real-world effectiveness and safety of IL-23 inhibitors in patients with psoriatic disease (psoriasis and/or psoriatic arthritis) treated in Costa Rica. The main questions it aims to answer are:Read full original descriptionShow less
National Registry of Patients With Psoriatic Disease Receiving Interleukin-23 Inhibitor Therapy Within the Costa Rican Social Security System
The goal of this observational registry study is to evaluate the real-world effectiveness and safety of IL-23 inhibitors in patients with psoriatic disease (psoriasis and/or psoriatic arthritis) treated in Costa Rica. The main questions it aims to answer are:
* Do IL-23 inhibitors (guselkumab or risankizumab) improve disease severity and quality of life in patients with psoriatic disease in routine clinical practice? * What is the safety profile and treatment persistence of IL-23 inhibitors in this population? * Patients receiving IL-23 inhibitors as part of their usual medical care will be followed longitudinally using standardized clinical measures (e.g., PASI, DLQI, DAPSA/BASDAI) and adverse-event reporting through a national registry.
Inclusion: Confirmed diagnosis of psoriatic disease, including psoriasis (any clinical variant) and/or psoriatic arthritis based on rheumatologic criteria; Receiving IL-23 inhibitor therapy (guselkumab or risankizumab); Treated within participating Costa Rican public health centers; Availability of sufficient clinical records to complete registry data (history, follow-up, labs); Age ≥12 years, any sex.
Exclusion: None specified (all patients meeting inclusion criteria are eligible).